Trial Profile
Multicenter, Open-label, Randomized Phase III to Evaluate Efficacy of Maintenance Treatment With Capecitabine Following Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary)
- Indications Early breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 14 Dec 2019 Results (N= 15,457), a metanalysis of prospective randomized trials assessing efficacy of Capecitabine as a part of neo adjuvant or adjuvant therapy in patients with early breast cancer, presented at the 42nd Annual San Antonio Breast Cancer Symposium
- 08 Sep 2017 Status changed from active, no longer recruiting to completed.
- 19 Jun 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.